Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) has unveiled a voluntary plan to repurchase up to HK$1.00 billion worth of its H shares within the 12-month period beginning 27 August 2026. The initiative will be executed under the 2026 H Share Repurchase Mandate approved at the company’s 16 June 2026 annual, H-shareholder, and A-shareholder meetings.

Management cited strong confidence in the Group’s long-term prospects and stated that the current H-share price does not fully reflect the company’s intrinsic value. Repurchased shares may be cancelled or retained as treasury stock, with the final treatment to be determined in line with market conditions and the mandate’s provisions.

If the programme is not completed before the next annual general meeting, further repurchases will require renewed authorization from shareholders at that meeting and the relevant class meetings. All transactions will comply with the Hong Kong Listing Rules, the Codes on Takeovers and Share Buy-backs, and other applicable regulations.

The board reiterated that timing, quantity, and pricing of any repurchases will depend on prevailing market conditions, and urged investors to exercise caution when dealing in the company’s securities. The announcement was approved by Chairman Chen Yuqing and released on 6 September 2026 in Shanghai.